Genedrive Regulatory News (GDR)

For release: 8 November

genedrive plc ("genedrive" or the "Company")

Directorate Change

genedrive plc, the near patient molecular diagnostics company, today announces that Chief Operating Officer, Allan Brown, will leave the Company as part of a planned change to management team structure. Dr Brown steps down from the Board with immediate effect and he will continue to be employed by the Company until 31 January 2018 to ensure an orderly handover.

Ian Gilham, Non-Executive Chairman of genedrive plc said, "Allan joined the company in 2014 and has played a key role in the development of the genedrive instrument and tests. On behalf of the board I'd like to thank Allan for his contributions and wish him the very best in his future plans."

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has received CE-IVD Certification and has been launched in Africa.

Further details can be found at: www.genedriveplc.com and www.genedrive.com